Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world

AIDS

Volumn 25, Issue 16, 2011, Pages 1939-1949

  Venkatesh, Kartik K ^a   Flanigan, Timothy P ^a   Mayer, Kenneth H ^b  

^a BROWN UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

AIDS; antiretroviral therapy; HIV; sexual risk behaviors; treatment

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL FACTOR;

CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DEVELOPING COUNTRY; ECOLOGICAL PROCEDURES; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREVENTION; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; REVIEW; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; SOCIAL PSYCHOLOGY; UNSAFE SEX; VIRUS LOAD;

ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; RISK-TAKING; UNSAFE SEX;

EID: 80054966344     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834b4ced     Document Type: Review

References (120)

1. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents; 2009. website. http://www.who.int/hiv/pub/ arv/rapid-advice-art.pdf. [Accessed 21 July 2011].
2. World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector; 2008. http://www.who.int/hiv/ mediacentre/2008progressreport/en/index.html. [Accessed 3 February 2009].
3. UNAIDS. UNAIDS/WHO AIDS epidemic update. UNAIDS/WHO; 2010. http://www.unaids.org/epidemic-update/. [Accessed 26 January 2011].
4. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29. (Pubitemid 36835816)
5. Palella F, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860. (Pubitemid 28135961)
6. De Cock K, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 2000; 283:1175-1182. (Pubitemid 30126606)
7. Baeten J, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:7729.
8. Cohen MS, Chen YQ, McCauley M, Gamble T, Hossemipon MC, Kumavasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 356:493-505.
9. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092-2098.
10. Johnston M, Fauci AS. An HIV vaccine: evolving concepts. N Engl J Med 2007; 356:2073-2081.
11. Cohen M, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis 2010; 50:S85-S95.
12. Granich R, Crowley S, Vitoria M, Lo YR, Souteyrand Y, Dye C, et al. Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc 2010; 12:1.
13. Hogben M, Liddon N. Disinhibition and risk compensation: scope, definitions, and perspective. Sex Transm Dis 2008; 35:1009-1010.
14. Marks G, Crepaz N, Senterfitt W, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States. J Acquir Immune Defic Syndr 2005; 39:446-453. (Pubitemid 41003791)
15. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior. JAMA 2006; 292:224-236.
16. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292:224-236. (Pubitemid 38918000)
17. Fisher J, Smith L. Secondary prevention of HIV infection: the current state of prevention for positives. Curr Opin HIV AIDS 2009; 4:279-287.
18. Attia S, Egger M, Mü ller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397-1404.
19. Salomon J, Hogan DR, Stover J, Stanecki KA, Walker N, Ghys PD, Schwartländer B. Integrating HIV prevention and treatment: from slogans to impact. PLoS Med 2005; 2:e16.
20. Cassell M, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 2006; 332:605-607. (Pubitemid 44365764)
21. Kelly J, Otto-Salaj LL, Sikkema KJ, Pinkerton SD, Bloom FR. Implications of HIV treatment advances for behavioral research on AIDS: protease inhibitors and new challenges in HIV secondary prevention. Health Psychol 1998; 17:310-319. (Pubitemid 28345938)
22. Eaton L, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr HIV/AIDS Rep 2007; 4:165-172.
23. Lalani T, Hicks C. Does antiretroviral therapy prevent HIV transmission to sexual partners? Curr Infect Dis Rep 2008; 10:140-145.
24. Mayer K, Venkatesh KK. Antiretroviral therapy for HIV prevention: current status and future prospects. Am J Public Health 2010; 100:1867-1876.
25. Boily M, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118-129.
26. Cu-Uvin S, CaliendoAM, Reinert S,Chang A, Juliano-Remollino C, Flanigan TP, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415-421. (Pubitemid 30182438)
27. Vernazza P, Gilliam BL, Flepp M, Dyer JR, Frank AC, Fiscus SA, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997; 11:1249-1254. (Pubitemid 27298091)
28. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
29. Blower S, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-654. (Pubitemid 30070912)
30. Velasco-Hernandez J, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-493. (Pubitemid 34826854)
31. Gray R, Li X, Wawer MJ, Gange SJ, Serwadda D, Sewankambo NK, et al. Rakai Project Group. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS 2003; 17:1941-1951. (Pubitemid 37070280)
32. Law M, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15:1287-1294. (Pubitemid 32592362)
33. Abbas U, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2007; 2:e875.
34. Granich R, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48-57.
35. Walensky R, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, et al. CEPAC Investigators. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010; 51:392-400.
36. Stolte I, Dukers NH, Geskus RB, Coutinho RA, de Wit JB. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS 2004; 18:303-309. (Pubitemid 38253454)
37. Dukers N, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS 2001; 15:369-378. (Pubitemid 32163823)
38. Ostrow D, Fox KJ, Chmiel JS, Silvestre A, Visscher BR, Vanable PA, et al. Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS 2002; 16:775-780. (Pubitemid 34274468)
39. Tun W, Gange SJ, Vlahov D, Strathdee SA, Celentano DD. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users. Clin Infect Dis 2004; 38:1167-1174. (Pubitemid 38951266)
40. Eisele T, Mathews C, Chopra M, Brown L, Silvestre E, Daries V, Kendall C. High levels of risk behavior among people living with HIV initiating and waiting to start antiretroviral therapy in Cape Town South Africa. AIDS Behav 2008; 12:570-577. (Pubitemid 351873634)
41. Kaida A, Gray G, Bastos FI, Andia I, Maier M, McIntyre J, et al. The relationship between HAART use and sexual activity among HIV-positive women of reproductive age in Brazil, South Africa, and Uganda. AIDS Care 2008; 20:21-25. (Pubitemid 351264535)
42. Sarna A, Luchters SM, Geibel S, Kaai S, Munyao P, Shikely KS, et al. Sexual risk behaviour and HAART: a comparative study of HIV-infected persons on HAART and on preventive therapy in Kenya. Int J STD AIDS 2008; 19:85-89. (Pubitemid 351738811)
43. Moatti J, Prudhomme J, Traore DC, Juillet-Amari A, Akribi HA, Msellati P. Côte d'Ivoire HIV Drug Access Initiative Socio-Behavioural Evaluation Group. Access to antiretroviral treatment and sexual behaviours of HIV-infected patients aware of their serostatus in Côte d'Ivoire. AIDS 2003; 17:S69-S77. (Pubitemid 36951672)
44. Bateganya M, Colfax G, Shafer LA, Kityo C, Mugyenyi P, Serwadda D, et al. Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral-naive and-experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. AIDS Patient Care STDs 2005; 19:760-768. (Pubitemid 41705172)
45. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, Were W, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85-92. (Pubitemid 41818118)
46. Venkatesh KK, Srikrishnan AK, Safren SA, Triche EW, Thamburaj E, Prasad L, et al. Sexual risk behaviors among HIV-infected South Indian couples in the HAART era: implications for reproductive health and HIV care delivery. AIDS Care 2011; 23:722-733.
47. Marcellin F, Bonono CR, Blache J, Carrieri MP, Spire B, Koulla-Shiro S. EVAL Study Group. Higher risk of unsafe sex and impaired quality of life among patients not receiving antiretroviral therapy in Cameroon: results from the EVAL survey (ANRS 12-116). AIDS 2010; 24:S17-S25.
48. Dia A, Marcellin F, Bonono R-C, Boyer S, Bouhnik A-D, Protopopescu C, et al. the EVAL Study Group. Prevalence of unsafe sex with one's steady partner either HIV-negative or of unknown HIV status and associated determinants in Cameroon (EVAL ANRS12-16 survey). Sex Transm Infect 2010; 86:148-154.
49. Venkatesh K, de Bruyn G, Lurie MN, Modisenyane T, Triche EW, Gray GE, et al. Sexual risk behaviors among HIV-infected South African men and women with their partners in a primary care program: implications for couples-based prevention. AIDS Behav 2011 (in press).
50. Bunnell R, Ekwaru J, King R, Bechange S, Moore D, Khana K, et al. 3-Year follow-up of sexual behavior and HIV transmission risk of persons taking ART in rural Uganda. 15th Conference on Retroviruses and Opportunistic Infections. Boston; 2008.
51. McClelland R, Graham SM, Richardson BA, Peshu N, Masese LN, Wanje GH, et al. Treatment with antiretroviral therapy is not associated with increased sexual risk behavior in Kenyan female sex workers. AIDS 2010; 24:891-897.
52. Venkatesh K, de Bruyn G, Lurie MN, Mohapi L, Pronyk P, Moshabela M, et al. Decreased sexual risk behavior in the era of HAART among HIV-infected urban and rural South Africans attending primary care clinics. AIDS 2010; 24: 2687-2696.
53. Peltzer K, Ramlagan S. Safer sexual behaviours after 1 year of antiretroviral treatment in KwaZulu-Natal, South Africa: a prospective cohort study. Sexual Health 2010; 7:135-141.
54. Luchters S, Sarna A, Geibel S, Chersich MF, Munyao P, Kaai S, et al. Safer sexual behaviors after 12 months of antiretroviral treatment in Mombasa, Kenya: a prospective cohort. AIDS Patient Care STDs 2008; 22:587-594. (Pubitemid 352040056)
55. Wanyama J, Kasibante D, Kayiira P, Wandera B, Kambugu A. Sexual behavior of HIVR persons before and after 1 year of ART at the Infectious Diseases Clinic, Kampala, Uganda. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco; 2010.
56. Diabaté S, Alary M, Koffi CK. Short-term increase in unsafe sexual behaviour after initiation of HAART in Cô te d'Ivoire. AIDS 2008; 22:154-156. (Pubitemid 350294892)
57. Lurie M, Pronyk P, de Moor E, Heyer A, de Bruyn G, Struthers H, et al. Sexual behavior and reproductive health among HIV-infected patients in urban and rural South Africa. J Acquir Immune Defic Syndr 2008; 47:484-493. (Pubitemid 351366965)
58. Kiene S, Christie S, Cornman DH, Fisher WA, Shuper PA, Pillay S, et al. Sexual risk behaviour among HIV-positive individuals in clinical care in urban KwaZulu-Natal, South Africa. AIDS 2006; 20:1781-1784. (Pubitemid 44299372)
59. Kennedy C, O'Reilly K, Medley A, Sweat M. The impact of HIV treatment on risk behaviour in developing countries: a systematic review. AIDS Care 2007; 19:707-720. (Pubitemid 46944272)
60. Venkatesh K, Srikrishnan AK, Mayer KH, Kumarasamy N, Raminani S, Thamburaj E, et al. Predictors of nonadherence to HAART among HIV-infected South Indians in clinical care: implications for developing adherence interventions in resource-limited settings. AIDS Patient Care STDs 2010; 24:795-803.
61. Eisele T, Mathews C, Chopra M, Lurie MN, Brown L, Dewing S, Kendall C. Changes in risk behavior among HIV-positive patients during their first year of antiretroviral therapy in Cape Town South Africa. AIDS Behav 2008; 13:1097-1105.
62. Kalichman S, Simbayi LC. HIV testing attitudes, AIDS stigma, and voluntary HIV counseling and testing in a black township in Cape Town, South Africa. Sex Transm Infect 2003; 9:442-447. (Pubitemid 38021401)
63. Cohen C, Montandon M, Carrico AW, Shiboski S, Bostrom A, Obure A, et al. Association of attitudes and beliefs towards antiretroviral therapy with HIV-seroprevalence in the general population of Kisumu, Kenya. PLoS One 2009; 4:e4573.
64. Bechange S, Bunnell R, Awor A, Moore D, King R, Mermin J, et al. Two-year follow-up of sexual behavior among HIVuninfected household members of adults taking antiretroviral therapy in Uganda: no evidence of disinhibition. AIDS Behav 2010; 14:816-823.
65. Boulle A, Hilderbrand K, Menten J, Coetzee D, Ford N, Matthys F, et al. Exploring HIV risk perception and behaviour in the context of antiretroviral treatment: results from a township household survey. AIDS Care 2008; 20:771-781.
66. Venkatesh K, Madiba P, De Bruyn G, Lurie MN, Coates TJ, Gray GE. Who gets tested for HIV in a South African Urban township? Implications for test and treat and gender-based prevention interventions. J Acquir Immune Defic Syndr 2010; 56:151-165.
67. Gregson S, Garnett GP. Antiretroviral treatment is a behavioural intervention: but why? AIDS 2010; 24:2739-2740.
68. Garnett G, Gazzard B. Risk of HIV transmission in discordant couples. Lancet 2008; 372:270-271. (Pubitemid 352020422)
69. Eaton L, Kalichman SC, O'Connell DA, Karchner WD. A strategy for selecting sexual partners believed to pose little/no risks for HIV: serosorting and its implications for HIV transmission. AIDS Care 2009; 21:1279-1288.
70. Suarez T, Kelly JA, Pinkerton SD, Stevenson YL, Hayat M, Smith MD, Erti T. Influence of a partner's HIV serostatus, use of highly active antiretroviral therapy, and viral load on perceptions of sexual risk behavior in a community sample of men who have sex with men. J Acquir Immune Defic Syndr 2001; 28:471-477. (Pubitemid 34033200)
71. Dunkle K, Stephenson R, Karita E, Chomba E, Kayitenkore K, Vwalika C, et al. New heterosexually transmitted HIV infections in married or cohabiting couples in urban Zambia and Rwanda: an analysis of survey and clinical data. Lancet 2008; 371:2183-2191. (Pubitemid 351885039)
72. Hugonnet S, Mosha F, Todd J, Mugeye K, Klokke A, Ndeki L, et al. Incidence of HIV infection in stable sexual partnerships: a retrospective cohort study of 1802 couples inMwanza Region, Tanzania. J Acquir Immune Defic Syndr 2002; 30:73-80. (Pubitemid 34506690)
73. Allen S, Meinzen-Derr J, Kautzman M, Zulu I, Trask S, Fideli U, et al. Sexual behavior of HIV discordant couples after HIV counseling and testing. AIDS 2003; 17:733-740. (Pubitemid 36521080)
74. Guthrie B, de Bruyn G, Farquhar C. HIV-1-discordant couples in sub-Saharan Africa: explanations and implications for high rates of discordancy. Curr HIV Res 2007; 5:416-429. (Pubitemid 47040483)
75. Maier M, Andia I, Emenyonu N, Guzman D, Kaida A, Pepper L, et al. Antiretroviral therapy is associated with increased fertility desire, but not pregnancy or live birth, among HIVR women in an early HIV treatment program in rural Uganda. AIDS Behav 2008; 13:28-37.
76. Barreiro P, del Romero J, Leal M, Hernando V, Asencio R, de Mendoza C, et al. Spanish HIV-Discordant Study Group. Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:324-326. (Pubitemid 44674013)
77. Savasi V, Parrilla B, Ratti M, Ferrazzi E. Reproductive assistance in HIV-1 discordant couples. Curr Opin Obstet Gynecol 2008; 20:205-210. (Pubitemid 351643505)
78. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al.; the CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
79. Grant R, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al., iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
80. Kalichman S. Co-occurrence of treatment nonadherence and continued HIV transmission risk behaviors: implications for positive prevention interventions. Psychosom Med 2008; 70:593-597.
81. Kalichman S, Cherry C, Kalichman MO, Amaral CM, White D, Pope H, et al. Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. Am J Public Health 2011; 101:531-538.
82. Fisher J, Bang H, Kapiga SH. The association between HIV infection and alcohol use: a systematic review and metaanalysis of African studies. Sex Transm Dis 2007; 34:856-863. (Pubitemid 350287498)
83. Kalichman S, Simbayi LC, Kaufman M, Cain D, Jooste S. Alcohol use and sexual risks for HIV/AIDS in sub-Saharan Africa: systematic review of empirical findings. Prev Sci 2007; 8:141-151.
84. Peltzer K, Ramlagan S. Perceived stigma among patients receiving antiretroviral therapy: a prospective study in KwaZulu-Natal, South Africa. AIDS Care 2011; 23:60-68.
85. Pearson C, Micek MA, Pfeiffer J, Montoya P, Matediane E, Jonasse T, et al. One year after ART initiation: psychosocial factors associated with stigma among HIV-positive Mozambicans. AIDS Behav 2009; 13:1189-1196.
86. Kairania R, Gray RH, Kiwanuka N, Makumbi F, Sewankambo NK, Serwadda D, et al. Disclosure of HIV results among discordant couples in Rakai, Uganda: a facilitated couple counselling approach. AIDS Care 2010; 22:1041-1051.
87. Wong L, Rooyen HV, Modiba P, Richter L, Gray G, McIntyre JA, et al. Test and tell: correlates and consequences of testing and disclosure of HIV status in South Africa (HPTN 043 Project Accept). J Acquir Immune Defic Syndr 2009; 50:215-222.
88. Simbayi L, Kalichman SC, Strebel A, Cloete A, Henda N, Mqeketo A. Disclosure of HIV status to sex partners and sexual risk behaviours among HIV-positive men and women, Cape Town, South Africa. Sex Transm Infect 2007; 83:29-34. (Pubitemid 46293802)
89. Crepaz N, Lyles CM, Wolitski RJ, Passin WF, Rama SM, Herbst JH, et al. HIV/AIDS Prevention Research Synthesis (PRS) Team. Do prevention interventions reduce HIV risk behaviours among people living with HIV? A meta-analytic review of controlled trials. AIDS 2006; 20:143-157.
90. Kalichman S, Ntseane D, Nthomang K, Segwabe M, Phorano O, Simbayi LC. Recent multiple sexual partners and HIV transmission risks among people living with HIV/AIDS in Botswana. Sex Transm Infect 2007; 83:371-375. (Pubitemid 47242485)
91. Protopopescu C, Marcellin F, Préau M, Gabillard D, Moh R, Minga A, et al. Psychosocial correlates of inconsistent condom use among HIV-infected patients enrolled in a structured ART interruptions trial in Côte d'Ivoire: results from the TRIVACAN trial (ANRS 1269). Trop Med Int Health 2010; 15:706-712.
92. Baral S, Sifakis F, Cleghorn F, Beyrer C. Elevated risk for HIV infection among men who have sex with men in low-and middle-income countries 2000-2006: a systematic review. PLoS Med 2007; 4:e339.
93. van Griensven F, de Lind van Wijngaarden JW, Baral S, Grulich A. The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS 2009; 4:300-307.
94. Mayer K, Mimiaga MJ, Safren SA. Out of the closet and into public health focus: HIV and STDs in men who have sex with men in middle income and resource-limited countries. Sex Transm Dis 2009; 37:205-206.
95. Kumta S, Lurie M, Weitzen S, Jerajani H, Gogate A, Row-kavi A, et al. Bisexuality, sexual risk taking, and HIV prevalence among men who have sex with men accessing voluntary counseling and testing services in Mumbai, India. J Acquir Immune Defic Syndr 2010; 53:227-233.
96. Fideli U, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001; 17:901-910. (Pubitemid 32881333)
97. Tovanabutra S, Robison V, Wongtrakul J, Sennum S, Suriyanon V, Kingkeow D, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002; 29:275-283. (Pubitemid 34208536)
98. Sullivan P, Kayitenkore K, Chomba E, Karita E, Mwananyanda L, Vwalika C, et al. Reduction of HIV transmission risk and high risk sex while prescribed ART: results from discordant couples in Rwanda and Zambia. 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montreal; 2009.
99. Fang C, Hsu HM, Twu SJ, Chen MY, Chang YY, Hwang JS, et al. Division of AIDS and STD, Center for Disease Control, Department of Health, Executive Yuan. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004; 190:879-885. (Pubitemid 39120963)
100. Montaner J, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010; 376:532-539.
101. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, Colfax GN. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 2010; 5:e11068.
102. Jansen I, Geskus R, Davidovich U, Coutinho R, Prins M, Stolte I. Increasing trend in HIV-1 incidence among young men who have sex with men inAmsterdam: a 25-year prospective cohort study. 17th Conference on Retroviruses and Opportunistic Infections. San Francisco; 27 February to 2 March 2010.
103. Wawer M, Gray R H, Sewankambo N K, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-1409. (Pubitemid 40563350)
104. Brenner B, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, et al. Quebec Primary HIV Infection Study Group. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007; 195:951-959. (Pubitemid 46452099)
105. Pettifor A, Macphail C, Corneli A, Sibeko J, Kamanga G, Rosenberg N, et al.; NIAID Center for HIV/AIDS Vaccine Immunology. Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. AIDS Behav 2010; 15:1243-1250.
106. Eron J, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F, Alcorn TM, Fiscus SA, Cohen MS. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 1998; 12:F181-F191.
107. Taylor S, Pereira AS. Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect 2001; 77:4-11. (Pubitemid 32142781)
108. Ward H, Rönn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5:305-310.
109. Schroder K, Carey MP, Vanable PA. Methodological challenges in research on sexual risk behavior: II. Accuracy of self-reports. Ann Behav Med 2003; 26:104-123. (Pubitemid 37271597)
110. Buvé A, Lagarde E, Caraë l M, Rutenberg N, Ferry B, Glynn JR, et al. Study Group on Heterogeneity of HIV Epidemics in African Cities. Interpreting sexual behaviour data: validity issues in the multicentre study on factors determining the differential spread of HIV in four African cities. AIDS 2001; 15:S117-S126. (Pubitemid 32913011)
111. Langhaug L, Sherr L, Cowan FM. How to improve the validity of sexual behaviour reporting: systematic review of questionnaire delivery modes in developing countries. Trop Med Int Health 2010; 15:362-381.
112. Langhaug L, Cheung YB, Pascoe SJ, Chirawu P,Woelk G, Hayes RJ, Cowan FM. How you ask really matters: randomised comparison of four sexual behaviour questionnaire delivery modes in Zimbabwean youth. Sex Transm Dis 2010; 87:165-173.
113. Cohen M, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007; 146:591-601. (Pubitemid 351650540)
114. Mayer K, Venkatesh, KK. Chemoprophylaxis for HIV prevention: new opportunities and new questions. J Acquir Immune Defic Syndr 2010; 55 (Suppl 2):S122-S127.
115. Venkatesh K, Lurie MN, Mayer KH. How HIV treatment could result in effective prevention. Future Virol 2010; 5:405-415.
116. Montaner J, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, Harrigan PR. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368:531-536. (Pubitemid 44142776)
117. Cohen M, Kaleebu P, Coates T. Prevention of the sexual transmission of HIV-1: preparing for success. J Int AIDS Soc 2008; 11:4.
118. Janssen RS, Holtgrave DR, Valdiserri RO, Shepherd M, Gayle HD, De Cock KM. The serostatus approach to fighting the HIV epidemic: prevention strategies for infected individuals. Am J Public Health 2001; 19:1019-1024. (Pubitemid 32574820)
119. Kurth A, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep 2010; 8:62-72.
120. Coates T, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 2008; 372:669-684.